Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Evommune, Inc.NYSE: EVMN
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 297.3% from a year ago
Total current assets stood at $215.86M at the end of Q1 FY2026, up 297.3% from a year earlier and up 40.6% from the prior quarter.
Context
- Total current assets amounted to 66.9% of total assets at the end of Q1 FY2026, down 30.0 pp from a year earlier.
- Total current assets increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +297.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 153.48M USD
- Year-over-year change
- +107.4%
- 2-year CAGR
- +38.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 153.48M | +107.4% |
| FY2024 | 2024-12-31 | 73.99M | -7.6% |
| FY2023 | 2023-12-31 | 80.03M | — |
Total Current Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total current assets of $215.86M is the 5th highest of the 10 companies compared; the peer median is $126.33M.
- Its year-over-year change of +297.3% is the 2nd highest of 10, against a peer median of +5.1%.
- Total current assets amounts to 66.9% of total assets for EVMN, versus a peer median of 66.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.46B | +312.8% | +46.7% | 66.7% | |
FTREFortrea Holdings Inc. | Jun 2026 | $923.6M | -3.8% | -10.4% | 34.0% |
| Sep 2026 | $532.4M | +82.5% | -24.6% | 45.3% | |
| Mar 2026 | $249.5M | -23.7% | +23.9% | 86.6% | |
EVMNEvommune, Inc. | Mar 2026 | $215.86M | +297.3% | — | 66.9% |
| Mar 2026 | $126.33M | +5.1% | -33.5% | 96.1% | |
CLYMClimb Bio, Inc. | Mar 2026 | $113.4M | +13.1% | -7.7% | 74.4% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $88.74M | -47.8% | +2.5% | 83.8% |
| Mar 2026 | $79.65M | +2.4% | -15.9% | 61.6% | |
| Mar 2026 | $65.13M | +21.6% | -19.4% | 22.2% | |
| Peer median (excluding EVMN) | $126.33M | +5.1% | -10.4% | 66.7% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.